Alzamend Neuro Inc. [NASDAQ: ALZN] slipped around -0.24 points on Wednesday, while shares priced at $1.94 at the close of the session, down -11.01%. The company report on December 17, 2021 that Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s.
Data shows that AL001 is bioequivalent to the marketed lithium carbonate product and the shapes of the lithium plasma concentration versus time curves are similar.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received positive topline data from its Phase 1 clinical trial for AL001. The purpose of the Phase 1 first-in-human study was to determine the pharmacokinetics, safety and tolerability of AL001 so as to target doses for a planned Phase 2 multiple ascending dose study in Alzheimer’s patients. AL001 is a lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer’s disease.
Compared to the average trading volume of 7.26M shares, ALZN reached a trading volume of 2445550 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Alzamend Neuro Inc. [ALZN]?
Ascendiant Capital Markets have made an estimate for Alzamend Neuro Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 01, 2021.
The Average True Range (ATR) for Alzamend Neuro Inc. is set at 0.26 The Price to Book ratio for the last quarter was 13.86, with the Price to Cash per share for the same quarter was set at 0.15.
How has ALZN stock performed recently?
Alzamend Neuro Inc. [ALZN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.01. With this latest performance, ALZN shares dropped by -12.61% in over the last four-week period, additionally sinking by -77.80% over the last 6 months .
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALZN stock in for the last two-week period is set at 41.90, with the RSI for the last a single of trading hit 37.76, and the three-weeks RSI is set at 43.35 for Alzamend Neuro Inc. [ALZN]. The present Moving Average for the last 50 days of trading for this stock 2.24, while it was recorded at 2.11 for the last single week of trading.
Alzamend Neuro Inc. [ALZN]: Deeper insight into the fundamentals
Return on Total Capital for ALZN is now -312.43, given the latest momentum, and Return on Invested Capital for the company is -356.06. Return on Equity for this stock declined to -356.06, with Return on Assets sitting at -213.54. When it comes to the capital structure of this company, Alzamend Neuro Inc. [ALZN] has a Total Debt to Total Equity ratio set at 16.66. Additionally, ALZN Total Debt to Total Capital is recorded at 14.28, with Total Debt to Total Assets ending up at 11.51.
Reflecting on the efficiency of the workforce at the company, Alzamend Neuro Inc. [ALZN] managed to generate an average of -$2,523,283 per employee.Alzamend Neuro Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.80 and a Current Ratio set at 9.80.
Insider trade positions for Alzamend Neuro Inc. [ALZN]
There are presently around $1 million, or 6.60% of ALZN stock, in the hands of institutional investors. The top three institutional holders of ALZN stocks are: TWO SIGMA INVESTMENTS, LP with ownership of 172,913, which is approximately New of the company’s market cap and around 8.10% of the total institutional ownership; SASSICAIA CAPITAL ADVISERS LLC, holding 93,762 shares of the stock with an approximate value of $0.2 million in ALZN stocks shares; and SUSQUEHANNA INTERNATIONAL GROUP, LLP, currently with $0.2 million in ALZN stock with ownership of nearly 61.803% of the company’s market capitalization.
Positions in Alzamend Neuro Inc. stocks held by institutional investors increased at the end of December and at the time of the December reporting period, where 16 institutional holders increased their position in Alzamend Neuro Inc. [NASDAQ:ALZN] by around 504,880 shares. Additionally, 6 investors decreased positions by around 155,569 shares, while 0 investors held positions by with 15,476 shares. The mentioned changes placed institutional holdings at 644,973 shares, according to the latest SEC report filing. ALZN stock had 11 new institutional investments in for a total of 422,048 shares, while 5 institutional investors sold positions of 76,240 shares during the same period.